Sökning: WFRF:(Pozzi Emanuela) >
Bevacizumab, temozo...
Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma : comprehensive safety results during and after first-line therapy
-
Saran, Frank (författare)
-
Chinot, Olivier L. (författare)
-
- Henriksson, Roger (författare)
- Umeå universitet,Onkologi
-
visa fler...
-
Mason, Warren (författare)
-
Wick, Wolfgang (författare)
-
Cloughesy, Timothy (författare)
-
Dhar, Sunita (författare)
-
Pozzi, Emanuela (författare)
-
Garcia, Josep (författare)
-
Nishikawa, Ryo (författare)
-
visa färre...
-
(creator_code:org_t)
- 2016-01-24
- 2016
- Engelska.
-
Ingår i: Neuro-Oncology. - : Oxford University Press (OUP). - 1522-8517 .- 1523-5866. ; 18:7, s. 991-1001
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background. The proposed use of bevacizumab with radiotherapy/temozolomide for newly diagnosed glioblastoma raised potential safety concerns. Bevacizumab has been linked with stroke, bleeding events, and wound-healing complications in other tumor types; these events are of particular concern for glioblastoma (highly vascular tumors that are usually resected). Published data on the interaction of bevacizumab with radiotherapy/temozolomide are also limited. We report safety data from a phase III randomized trial (Avastin in Glioblastoma), focusing on these considerations. Methods. Eligible patients received: radiotherapy and temozolomide plus bevacizumab/placebo, 6 cycles; a 4-week treatment break; temozolomide plus bevacizumab/placebo, 6 cycles; and bevacizumab/placebo until progression. Data on adverse events (AEs) were collected throughout. Results. Bevacizumab-treated patients (n = 461) had a longer median safety follow-up time (12.3 vs 8.5 mo), and a higher proportion completed 6 cycles of maintenance temozolomide (64.6% vs 36.9%) versus placebo (n = 450). The incidences of relevant AEs (bevacizumab vs placebo, respectively) were: arterial thromboembolic events (5.9% vs 1.6%); cerebral hemorrhage (3.3% vs 2.0%); wound-healing complications (6.9% vs 4.7%); thrombocytopenia (34.1% vs 27.3%); radiotherapy-associated skin injury (8.2% vs 9.3%); alopecia (39.0% vs 36.0%); gastrointestinal perforation (including gastrointestinal abscesses and fistulae, 1.7% vs 0.4%); and radiotherapy-associated injury (0.4% vs 0.0%). Overall, 15.8% and 23.8% of bevacizumab-and placebo-treated patients had surgery (including biopsy) after progression. Within 30 days of postprogression surgery, AE incidence was 10.9% (bevacizumab) and 23.4% (placebo). Conclusion. The safety profile was consistent with that expected from radiotherapy/temozolomide plus bevacizumab. The increased AE incidence with bevacizumab did not impact patients' ability to receive standard-of-care treatment or to undergo further surgery.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- adverse events
- AVAglio
- bevacizumab
- glioblastoma
- safety
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Saran, Frank
-
Chinot, Olivier ...
-
Henriksson, Roge ...
-
Mason, Warren
-
Wick, Wolfgang
-
Cloughesy, Timot ...
-
visa fler...
-
Dhar, Sunita
-
Pozzi, Emanuela
-
Garcia, Josep
-
Nishikawa, Ryo
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Neuro-Oncology
- Av lärosätet
-
Umeå universitet